The following stories appear in full on today's Vidyya Medical News Service Web site.
Cancer registries are a little known, increasingly important part of the medical communities knowledge base about cancer. Cancer surveillance serves as the foundation for a national, comprehensive strategy to reduce illness and death from cancer. Such surveillance is the indispensable tool that enables public health professionals at the national, state, and local levels to better understand and tackle the cancer burden. Information derived through surveillance is critical for directing effective cancer prevention and control programs focused on preventing risk behaviors for cancer, such as tobacco use and poor diet, as well as reducing environmental risk factors. Such information is also essential in identifying when and where cancer screening efforts should be enhanced. Read more about these registries in today's Vidyya.
The morning after....Hospitalized after suffering his fourth heart attack, Vice Presidential candidate Dick Cheney is setting a bad example for other Americans by chowing down on the very foods that damaged his heart in the first place, say doctors from the Physicians Committee for Responsible Medicine, a nonprofit health organization based in Washington, D.C. On Thanksgiving Day, the day after entering George Washington University Hospital with chest pains, Cheney gobbled up "turkey with all the trimmings."
The VIGOR (Vioxx Gastrointestinal Outcomes Research) study has found that Vioxx® (rofecoxib) significantly reduced the risk of serious gastrointestinal side effects by 50 percent compared to the non-steroidal anti-inflammatory drug (NSAID) naproxen and significantly reduced the risk of the most serious of these GI side effects by 60 percent. The study was published for the first time in this week's New England Journal of Medicine
A study published in the November 22 issue of the Journal of the American Medical Association (JAMA) suggests that stratified care which included Zomig® (zolmitripan) Tablets is a more effective migraine treatment strategy than step care approaches.
Zomig is a potent, orally bioavailable, selective 5-HT1B/1D receptor agonist, indicated for the acute treatment of migraine attacks, with or without aura, in adults. Preclinical studies and early clinical pharmacology studies indicate that ZOMIG may act at both central and peripheral sites of the trigeminovascular system to constrict cranial blood vessels and inhibit vasoactive peptide release which results in inflammatory responses and pain.25 Zomig may also act centrally to inhibit the transmission of pain signals from the brainstem to higher brain centers. Get the full prescribing information in today's issue.
As always, we hope you enjoy the issue.